CPT 90386: Rho(D) Immunoglobulin to Prevent Hemolytic Disease of the Newborn
CPT code 90386 denotes Rho(D) (Rhesus D) immunoglobulin, a plasma‑derived antibody preparation used to provide passive immunity and prevent Rh alloimmunization and hemolytic disease of the newborn. Nationally, this code covers a critical preventive intervention in obstetric care that reduces morbidity associated with Rh incompatibility and supports maternal and neonatal safety.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the product and its typical sites of service, plus an overview of payer coverage considerations and common billing modifiers. The publication summarizes reimbursement benchmarks where available, highlights relevant policy and coverage updates impacting access, and clarifies billing and coding practices tied to this injectable biologic.
This resource is intended for billing professionals, practice managers, and policy analysts seeking a clear, national‑level briefing on clinical use, coding designation, and payer coverage patterns for Rho(D) immunoglobulin under CPT code 90386.
Customize your policy alerts
Sign up for cpt 90386 policy alerts
Get alerted when payer policies referencing 90386 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 90386 describes Rho(D) (Rhesus D) immunoglobulin derived from plasma of healthy, specifically immunized human donors. This biologic provides passive immunity by supplying anti-Rh(D) antibodies to prevent Rh (Rhesus) alloimmunization and hemolytic disease of the newborn.
-
Service type: Administration of Rho(D) immunoglobulin as a passive immunization therapy
-
Typical site of service: Outpatient clinic, obstetrics clinic, hospital outpatient department, or other ambulatory care settings where injectable biologics are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.